Diabetes patients who underwent percutaneous coronary intervention for STEMI had nearly four times the mortality rate of those without diabetes, according to results from the INFUSE-AMI trial. Researchers also found those with diabetes had more extensive left anterior descending artery disease and a higher 30-day revascularization rate compared with the nondiabetes cohort. The findings appear in the journal Catheterization and Cardiovascular Interventions.

Related Summaries